Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25
Zogenix (NASDAQ: ZGNX) announced it will report its financial results for Q4 and full-year 2020 on February 25, 2021, at 4:30 PM ET. The company, based in Emeryville, California, focuses on developing therapies for rare diseases. Its lead product, FINTEPLA, is approved in the U.S. and Europe for treating Dravet syndrome. Zogenix is also advancing late-stage programs for seizures associated with Lennox-Gastaut syndrome and developing MT1621 for TK2 deficiency. A conference call will follow the earnings report to discuss the results.
- Zogenix's FINTEPLA has received FDA and EMA approval.
- The company has two late-stage development programs for rare epilepsy treatments.
- None.
EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2020 and host a corporate update conference call and webcast after the market close, on Thursday, February 25, 2021, at 4:30 PM Eastern Time.
| Conference Call Details | |
| Thursday, February 25, at 4:30 PM Eastern Time / 1:30 PM Pacific Time | |
| Toll Free: | 877-407-9716 |
| International: | 201-493-6779 |
| Conference ID: | 13715661 |
| Webcast: | http://public.viavid.com/index.php?id=143250 |
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic mitochondrial depletion disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for genetic rare epilepsies.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com
FAQ
When will Zogenix report its Q4 2020 financial results?
What is Zogenix's primary product for rare diseases?
What other programs is Zogenix developing?
What is the conference call ID for Zogenix's earnings call?
